Antimicrobial defense mechanisms are enhanced by antigen-specific T cell differentiation followed by activation of mononuclear phagocytes (1, 2). 3" Interferon (IFN-3,) ~ is an important mediator of both antimicrobial activity and hydrogen peroxide secretion in mononuclear phagocytes (3). A number of observations suggest that an immunological defect exists in lepromatous leprosy w_hich-allows the extensive replication of M. leprae within dermal macrophages (4). The skin lesions are relatively deprived of helper T cells (OKT4), which are an important source of IFN-3" (5-7). The exposure of peripheral blood T cells to M. leprae fails to result in appreciable T cell proliferation and synthesis of lymphokine, including IFN-3" (8-10). In contrast, the lymphocytes of patients with lepromatous leprosy can respond to l~ctins and other antigens to which they are sensitized (4, (8) (9) (10) (11) (12) (13) . This had lead to the concept of selective anergy in which, either due to the absence ofM. leprae-reactive T cells and/or the activity of suppressor cells or factors, macrophage activation does not occur and microbial dissemination ensues (1 1-23 ).
KAPLAN
ET AL. Pertinent demographic and diagnostic information based on the Ridley-Jopling classification (22) . LL, lepromatous leprosy; BL, borderline lepromatous; BB, mid-borderline; BT, borderline tuberculoid. Two patients had erythema nodosum leprosum (ENL) (Nos. Table I ). The nonresponder and low responder patients with lepromatous leprosy could not otherwise be distinguished on the basis of histopathologic classification, bacterial indices, or the duration and type of treatment (Table I ). When cells from lepromatous patients were tested for BCG-induced proliferation, 5 of 11 nonresponders (Nos. 6, 11, 12, 13, and 14) and 4 of 7 low responders (Nos. 18, 19, 22, 25) reacted. This confirms previous reports (11-13) on the presence of a BCG-reactive T cell population in patients unable to respond to M. leprae. T cells from all patients proliferated in response to Con A as reported (9) . Therefore, the T cell defect in lepromatous disease is specific for M. leprae but is manifested as both nonresponsive and hyporesponsive states.
Release of lFN-~, in Response to Antigen or Mitogen. The release of IFN-3, was used as an additional measure of T cell function. Patients classified as M. leprae nonresponders, based on antigen-induced proliferation, also failed to release (Table  III) . Cells from patients that proliferatet~ to BCG also released IFN-3, in response to this antigen. Con A induced high levels of IFN-3, release from most of the patients tested (Table III) . Therefore, any proliferative response of the cells to antigen or mitogen was accompanied by the concomitant release of IFN-7. The results are expressed as mean units IFN-7 released (measured by a direct radioimmunoassay) and mean stimulation index (SI) and standard deviation (SD) for each group. NT, not tested. * Patients that respond to BCG (see Table II ). The mean SI (SD) for all nonresponders to BCG was 5.9 (2.8) and, for all responders, 58.1 (64.5). 
Effect of Exogenous IL-2 on Proliferation and IFN-'y Release.
The effect of exogenous IL-2 on the proliferative response to antigen and mitogen was examined. The addition of a single dose of 3 U of rIL-2 at the beginning of the culture period resulted in a 2-15-fold increase in [3H]thymidine incorporation in all patients, compared with the no antigen control (Table II and Fig. 1 ). In the majority of low or nonresponders tested (15/22) , the addition of IL-2 and M. leprae, or IL-2 and BCG, gave an additive response. Only in 4 patients (Table   II , Nos. 8-10, 13) was the response more than the sum of the individual M.
leprae and IL-2 effects.
To ensure that functional IL-2 was available throughout the culture period, additional studies were performed in which IL-2 was added daily for 
Effects of Monocyte Depletion on Antigen and Mitogen Responses.
We next examined if the blood of lepromatous patients had suppressor cells that dampened the M. leprae response. Suppressor monocytes were considered first using the mAb 3C 10 and C*. This reagent specifically depletes monocytes, but dendritic cells, an accessory cell for many T-dependent responses, are unaffected (28) . In most experiments, B cells were also depleted together with monocytes to ensure that we were evaluating a T cell-proliferative response. The mAb elimination method was evaluated with BCG as antigen. 7 of 8 BCG responders showed significantly enhanced proliferation after monocyte depletion (Table IV, reduced (Table IV) . Therefore, it appears that monocytes are contributory accessory cells in mitogen responses, but are not required and may even be suppressive in the BCG system. When responses to M. leprae were studied in 3C 10 plus C*-treated leukocytes, only 1 of 8 nonresponders (Table IV, (Table IV) . These results indicate that monocyte depletion can enhance preexisting responses but seldom reverses nonresponsiveness.
Monocyte depletion also enhanced IFN-3, production in response to antigens, including BCG in BCG-reactive patients (Table V, Nos. 2, 6, I 1, 26, 28, 30, 31) and M. leprae in two low responders (Table V, Nos. 18, 26) . No enhancement of IFN-'y release was observed when monocytes were eliminated from nonresponsive patients.
To evaluate the possibility that monocytes could inhibit the response to IL-2, monocytes were depleted and then exogenous rIL-2 was added to cells from nonresponder patients. Exogenous rIL-2, in the presence or absence of monocytes, did not significantly enhance M. leprae-induced T cell proliferation (not shown).
Effects of Depletion of T Cell Subsets, in Combination with Monocyte Depletion and Addition of lL-2. T cell proliferation was next monitored in cultures depleted
of suppressor T cells (OKT8), monocytes (3C10), helper T cells (OKT4), or monocytes and suppressor T cells. Depletion of OKT8 + cells had no effect on proliferation to M. leprae or to BCG in nonresponder patients, but did reduce the Con A response (Table VI) . Combined depletion of monocytes and suppressor T cells (3C10 plus OKT8 plus C*) also had no effect on the response to M.
leprae. Depletion of OKT4 + T cells ablated the proliferation induced by Con A or BCG.
We also added 7.5 U of exogenous rIL-2 to the OKT4 and OKT8 antibody and C*-treated leukocytes (data not shown). IL-2 did not restore responses to IN The data are actual counts per minute for the complement (C*) control, and percent of C* control when cells were treated with 3C10 and C*. The percent depletion was calculated as described in Materials and Methods. Mean stimulation index (SI) and standard deviation (SD) are shown for each group. NT, not tested. For significance testing, the paired comparisons t test was used. * Patients that respond to BCG (see Table 11 ). t Data for all BCG nonresponders.
VITRO T CELL RESPONSIVENESS IN LEPROMATOUS LEPROSY
M. leprae in OKT8-cultures, but did restore proliferation in response to BCG in cultures depleted of OKT4 ÷ (helper) cells. This would suggest that the OKT4 + cells are the main source of endogenous IL-2 and that the remaining OKT4-OKT8 + T cells can proliferate if IL-2 is provided. We conclude that T cell anergy in lepromatous disease cannot be reversed by removing the OKT8 ÷ suppressor subset. Results are expressed as units IFN-7 produced. Cells were treated with complement only (C* control) or antimonocyte mAb and C* (3C10 + C*). NT, not tested. No Ag, no antigen control. * Patients that respond to BCG (See Table II ).
Discussion

Specific hyporesponsiveness of T cells to M. leprae antigens is well documented in lepromatous leprosy. It is manifested as diminished skin test responses to
TABLE VI
Effect of T Cell and Monocyte Depletion on the Proliferative Response to
Antigen and Mitogen Results are expressed as mean stimulation index ___ standard deviation. Cells were treated with complement only (C* control), antimonocyte mAb and C* (3C 10 + C*), antisuppressor T cell mAb and C* (OKT8 + C*), anti-helper T cell mAb and C* (OKT4 + C*), and antimonocyte and suppressor T cell mAb and C* (3C10 + OKT8 + C*). NT, not tested. The range of cpm incorporated in response to M. leprae was 500-4,800. The patients tested (not included in Table   I ) were all nonresponder LL with 0-14 yr of treatment. Results for BCG include only the two patients that responded to the antigen. Two patients were not tested for Con A.
lepromin antigens as well as an absence of T cell proliferation and lymphokine release in vitro (8, 9, 11, 12) . However, patients exhibit responsiveness to mitogenic lectins and to the M. leprae-related organism, BCG, irrespective of their ability to respond to M. leprae. Recent observations have raised the possibility that M. leprae-specific sensitized T cells are present in lepromatous disease, but that their function is compromised by inadequate release of IL-2 (10) and/ or suppressor T lymphocytes (15, 16, 18) or macrophages (19) (20) (21) .
Our findings in a substantial number of lepromatous patients from Bogota, Colombia and New York help clarify the deficiency in the cell-mediated immune response. Peripheral blood T cells from patients with lepromatous leprosy proliferate and release IFN-~, to varying degrees in response to M. leprae antigens in vitro (Tables II and III) . We noted that patients who were judged to be at the lepromatous pole by histopathologic and clinical criteria, actually fell into two groups. Approximately half were unable to generate a detectable response (nonresponders) and half were hyporesponders. T ceils from the latter group exhibited a 6.1 _+ 2.9-fold boost in proliferation in response to M. leprae challenge and, in some cases, in IFN-~" release. It is this latter group in which some success has been achieved in enhancing the response to M. leprae in vitro.
Experiments in which specific cell populations were depleted indicated that monocytes or their products, but not OKT8 + T cells, could depress the thymidine incorporation of T cells in response to M. leprae (Tables IV, V, and VI). This, however, was obtained only in responsive populations (hypo-and high responders), whereas cells from unresponsive patients were unaffected. Therefore, monocyte suppressor activity could not alone explain the anergic state. In addition, monocyte suppression was not limited to M. leprae, as it was observed in the response to BCG.
Studies from our laboratory (8) and those of others (10, 27, 28) have attempted to elucidate the capacity of IL-2 to reverse the unresponsiveness of T cells from patients with iepromatous leprosy. In the present study this parameter has been studied with an appreciation of the variable responses of lepromatous leprosy patients to M. leprae. The presence of exogenous IL-2 in cultures of cells from hyporesponsive patients enhances the M. leprae proliferation and IFN-~, release by these cells. Since IL-2 did not induce specific T cell function in the majority of M. leprae nonresponders, and because the stimulation of hyporesponders by M. leprae in the presence of IL-2 and in its absence were similar (about fourfold, Fig. 2) , we conclude that the IL-2 supplement did not lead to de novo sensitization, but instead appeared to expand already sensitized cells. These facts suggest that the absence of IL-2 production per se is not responsible for the anergic state. Our results conflict with the reports that responsiveness is restored after exposure of the cells to exogenous IL-2 (10, 28) . The discrepancy between our results and those of Haregewoin et al. (10) might be attributed to the heterogeneity of responsiveness of the lepromatous patients. Attempts to restore responsiveness with exogenous IL-2 would appear to be successful if many of the patients tested are low responders rather than nonresponders.
Although M. leprae are sequestered within phagolysosomes of dermal macrophages and Schwann cells, it is evident that antigen is gaining access to the immune system. Specifically, there are high levels of anti-M, leprae antibodies in lepromatous disease (31) . The immunoglobulins are primarily of the IgM subclass and therefore are likely to be to T cell-independent antigenic determinants. It is not known if the M. leprae determinants that are required for effective T cell stimulation are also accessible to the immune system. Both specific and nonspecific suppressor mechanisms could be operative within the infected dermis that might block sensitization. For example, recent evidence suggests a M. leprae antigen, the phenolic glycolipid I, specifically suppresses T cell proliferation in response to Con A in lepromatous patients (16) . Unfortunately, current in vitro methodology monitors previously sensitized T cell function rather than the priming stage of cell-mediated immunity. These experiments do not provide information on the capacity to prime cells in nonresponder patients relative to responders. There is intriguing data that sensitization to antigens other than M.
leprae is not effective in lepromatous disease (32, 33) , and we are pursuing this in current clinical trials. There are also genetic studies indicating that certain HLA phenotypes (DQ1) predispose individuals to the nonresponsiveness observed in iepromatous disease (34) . Many of these considerations can now be approached experimentally, and their elucidation should enrich our knowledge of cell-mediated immunity in man.
Summary
In lepromatous leprosy, there is extensive replication of Mycobacterium leprae (M. leprae) within dermal macrophages. This lack of microbial resistance has been attributed to a defective cell-mediated immune response to M. leprae antigens. We have examined the in vitro response of T cells to M. leprae to determine if hyporesponsiveness could be reversed. The study included 40 unselected patients from New York and from Colombia, most with the severe lepromatous form of the disease.
We first noted that lepromatous leprosy patients were of two types: those unable to respond, as assessed by T cell proliferation and immune (gamma) interferon (IFN--y) release, and a second group, exhibiting low but detectable responses relative to tuberculoid controls. When the effect of exogenous recombinant interleukin-2 (IL-2) on the response to M. leprae antigens was compared in the two groups, many of the low responders, but not the nonresponders, showed enhanced proliferation and IFN-3, release. To evaluate a possible suppressive effect of monocytes, these cells were eliminated with a cell-specific monoclonal antibody and complement. Depletion of monocytes often expanded preexisting weak responses but did not reverse the anergy of the M. leprae nonresponders. The enhancement was not M. leprae-specific, since it was also observed when bacillus Calmette-Guerin was the antigenic stimulus for proliferation and IFN-~, production. Removal of the suppressor T cell subset, with OKT8 antibody and complement, also did not restore responses in nonresponder patients. We conclude that a sizable number of iepromatous leprosy patients exhibit a low degree of responsiveness to M. leprae and that the responses can be enhanced in vitro with IL-2 or with monocyte depletion. Nonresponsiveness, however, cannot be reversed. Since currently available assays measure the function of previously sensitized T cells, suppressor mechanisms may yet contribute to defective cell-mediated immunity by impairing the initial sensitization to M. leprae antigens.
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